

S 2057

Pharmaceutical Regulation Conflict of Interest Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Government Operations and Politics

**Introduced:** Nov 1, 2017

**Current Status:** Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

**Latest Action:** Read twice and referred to the Committee on Homeland Security and Governmental Affairs. (Nov 1, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/2057>

Sponsor

**Name:** Sen. Baldwin, Tammy [D-WI]

**Party:** Democratic • **State:** WI • **Chamber:** Senate

Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Feinstein, Dianne [D-CA]	D · CA		Nov 1, 2017
Sen. Harris, Kamala D. [D-CA]	D · CA		Nov 1, 2017
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Nov 1, 2017
Sen. Markey, Edward J. [D-MA]	D · MA		Nov 1, 2017
Sen. Shaheen, Jeanne [D-NH]	D · NH		Nov 1, 2017
Sen. Udall, Tom [D-NM]	D · NM		Nov 1, 2017
Sen. Manchin, Joe, III [D-WV]	D · WV		Nov 8, 2017
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Nov 16, 2017

Committee Activity

Committee	Chamber	Activity	Date
Homeland Security and Governmental Affairs Committee	Senate	Referred To	Nov 1, 2017

Subjects & Policy Tags

**Policy Area:**

Government Operations and Politics

Related Bills

No related bills are listed.

## **Pharmaceutical Regulation Conflict of Interest Act**

This bill amends the Ethics in Government Act of 1978 to prohibit a pharmaceutical regulator from using his or her position as regulator to influence any matter that provides a direct or substantial pecuniary benefit to a former employer or client. The position of pharmaceutical regulator refers to any officer or employee occupying a supervisory position within the Drug Enforcement Administration or the Food and Drug Administration.

The bill also prohibits such a pharmaceutical regulator from participating in matters involving an individual or entity with whom the pharmaceutical regulator is negotiating future employment.

The bill expands restrictions on lobbying by such pharmaceutical regulators following separation from employment with a pharmaceutical regulatory agency.

## **Actions Timeline**

---

- **Nov 1, 2017:** Introduced in Senate
- **Nov 1, 2017:** Read twice and referred to the Committee on Homeland Security and Governmental Affairs.